Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants

Neuroscience and Biobehavioral Reviews

Volumn 22, Issue 2, 1998, Pages 325-333

  Baker, G B ^a   Fang, J ^a   Sinha, S ^a   Coutts, R T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Anticonvulsants; Antidepressants; Antipsychotics; Anxiolytics; Cytochrome P450; Genetic polymorphism; Isozymes; Metabolism; Selective serotonin reuptake inhibitors (SSRIs)

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CITALOPRAM; CYTOCHROME P450; DIAZEPAM; DRUG METABOLITE; FLUOXETINE; METOPROLOL; NEUROLEPTIC AGENT; PAROXETINE; PSYCHOTROPIC AGENT; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TERFENADINE; WARFARIN;

DRUG METABOLISM; DRUG SAFETY; DRUG TRANSFORMATION; ENZYME INDUCTION; ENZYME INHIBITION; GENETIC POLYMORPHISM; HUMAN; MENTAL DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0031924994     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(97)00018-3     Document Type: Article

References (154)

1. Baumann P. Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int. Clin. Psychopharmacol. 11:1996;5-11.
2. Boyer, W.F., Feighner, J.P., The efficacy of selective serotonin re-uptake inhibitors in depression, in: J.P. Feighner, W.F. Boyer (Eds.), Perspectives in Psychiatry, vol. 1, Selective Serotonin Re-Uptake Inhibitors. Chichester: John Wiley & Sons; 1991; 89-108.
3. Greenblatt D.J., Preskorn S.H., Cotreau M.M., Horst W.D., Harmatz J.S. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin. Pharmacol. Ther. 52:1992;479-486.
4. Warrington S.J. Clinical implications of the pharmacology of serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. 7:1992;13-19.
5. Black D.W., Wesner R., Bowers W., Gabel J. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch. Gen. Psychiatry. 50:1993;44-50.
6. Boyer W.F. Potential indications for the selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. 6:1992;5-12.
7. Den Boer J.A., Westenberg H.G.M. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology. 102:1990;85-94.
8. Hollister L.E., Claghorn J.L. New antidepressants. Annu. Rev. Pharmacol. Toxicol. 32:1993;165-177.
9. Humble H., Wistedt B. Serotonin, panic disorder and agoraphobia - short-term and long-term efficacy of citalopram in panic disorders. Int. Clin. Psychopharmacol. 6:1992;21-39.
10. Sheehan D.V., Raj B.A., Trehan R.R., Knapp E.L. Serotonin in panic disorder and social phobia. Int. Clin. Psychopharmacol. 8:1993;63-77.
11. Tollefson, G.D., Selective serotonin reuptake inhibitors, in: A.F. Schatzberg, C.B. Nemeroff (Eds.), Textbook in Psychopharmacology, Washington, DC, American Psychiatric Press, 1995, pp. 161-182.
12. Baumann P., Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int. Clin. Psychopharmacol. 10:1995;15-21.
13. Brøsen K., Skjelbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450llD6 - the source of the sparteine/debrisoquine oxidation polymorphism. Br. J. Clin. Pharacol. 32:1992;136-137.
14. Ereshefsky L., Riesenman C., Lam Y.M.F. Antidepressant drug interactions and the cytochrome P450 system: the role of cytochrome P450 2D6. Clin. Pharmacokinet. 29:1995;10-19.
15. Flockhart D.A. Drug interactions and the cytochrome P450 system: the role of cytochrome P450 2C19. Clin Pharmacokinet. 29:1995;53-59.
16. Otton S.V., Wu D., Joffe R.T., Cheung S.W., Sellers E.M. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin. Pharmacol. Ther. 53:1993;401-409.
17. Taylor D., Lader M. Cytochromines and psychotropic drug interactions. Br. J. Psychiatry. 168:1966;529-533.
18. von Moltke L.L., Greenblatt D.J., Schmider J., Harmatz J.S., Shader R.I. Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin. Pharmacokinet. 29:1995;33-44.
19. Wagner W., Vause E.W. Fluvoxamine: a review of global drug-drug interaction data. Clin. Pharmacokinet. 29:1995;26-32.
20. Brøsen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin. Invest. 71:1993;1002-1009.
21. Ciraulo D.A., Shader R.I. Fluoxetine drug-drug reactions: I. Antidepressants and antipsychotics. J. Clin. Psychopharmacol. 10:1990;48-50.
22. Ciraulo D.A., Shader R.I. Fluoxetine drug-drug reactions: II. Fluoxetine drug-drug interactions. J. Clin. Psychopharmacol. 10:1990;213-217.
23. DeVane, C.L., Pharmacokinetics of the newer antidepressants: clinical relevance. Am. J. Med. 97 (1994) 6A.13S-6A.23S.
24. Glue P., Banfield C. Psychiatry, psychopharmacology and P-450s. Hum. Psychopharmacol. 1:1996;97-114.
25. Harvey A.T., Preskorn S.H. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch. Gen. Psychiatry. 52:1995;783-784.
26. Messiha F.S. Fluoxetine: adverse effects and drug-drug interactions. Clin. Toxicol. 31:1993;603-630.
27. Meyer U.A., Amrein R., Balant L.P., Bertilsson L., Eichelbaum M., Guentert T.W., Henauer S., Jackson P., Laux G., Mikkelsen H., Peck C., Pollock B.G., Priest R., Sjöqvist F., Denlini-Stula A. Antidepressants and drug-metabolizing enzymes - expert group report. Acta Psychiat. Scand. 93:1966;71-79.
28. Nemeroff C.B., DeVane C.L., Pollock B.G. Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry. 153:1996;311-320.
29. Preskorn, S.H., Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors, 1st ed., Professional Communications Inc., Caddo, OK, 1996.
30. Gonzalez F.J. Human cytochrome P450: problems and prospects. Trends Pharmacol. Sci. 13:1992;346-352.
31. Nebert D.W., Nelson D.R., Coon M.J., Estabrook R.W., Feyereisen R., Fujii-Kuriyama Y., Gonzalez F.J., Guengerich F.P., Gunsalus I.C., Johnson E.F., Loper J.C., Sato R., Waterman M.R., Waxman D.J. The P450 superfamily: update on new sequences, gene mapping and recommend nomenclature. DNA Cell Biol. 10:1991;1-14.
32. Nelson D.R., Kamataki T., Waxman D.J., Guengerich F.L., Estabrook R.W., Feyereisen R., Gonzalez F.J., Coon M.J., Gunsalus I.C., Gotoh O., Okuda K., Nebert D.W. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 12:1993;1-51.
33. Gough A.C., Miles J.S., Spurr N.L., Moss J.E., Gaedigk A., Eichelbaum M., Wolf C.R. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature. 347:1990;773-776.
34. Kagimoto M., Heim M., Kagimoto K., Zeugin T., Meyer U.A. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. J. Biol. Chem. 265:1990;17209-17214.
35. Kroemer H.K., Eichelbaum M. 'It's the genes, stupid.' Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci. 56:1995;2285-2298.
36. Cholerton S., Daly A.K., Idle J.R. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol. Sci. 13:1992;434-439.
37. Coutts R.T. Polymorphism in the metabolism of drugs, including antidepressant drugs: Comments on phenotyping. J. Psychiatr. Neurosci. 19:1994;30-44.
38. Gaedigk A., Blum M., Gaedigk R., Eichelbaum M., Meyer U.A. Deletion of the entire cytrochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am. J. Human Genet. 48:1991;943-950.
39. DeVane C.L. Pharmacogenetics and drug metabolism of newer antidepressant agents. J. Clin. Psychiatry. 55(Suppl.):1994;38-45.
40. Fang, J., Bourin, M., Naylor Baker, G.B., Metabolism of risperiodone to 9-hydroxyrisperidone by recombinant human cytochrome P450 2D6, Proc. 19th Ann. Meeting, Ca. College Neuropsychopharmacol., Toronto, Canada.
41. Fischer V., Vogels B., Maurer G., Tynres R.E. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J. Pharmacol. Exp. Ther. 260:1992;1355-1360.
42. Mannens G., Huang M.L., Meuldermans W., Hendricks J., Woestenborghs R., Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug. Metab. Dispos. 21:1993;1134-1141.
43. Bertillson L., Arberg-Wistard A., Gustafsson L., Nordin C. Extremely rapid hydroxylation of desbrisoquine: a case report with implications for treatment with nortriptyline and other tricyclic antidepressants. Ther. Drug. Monit. 7:1985;478-480.
44. Johansson I., Lundqvist E., Bertilsson L., Dahl M.-L., Sjöqvist F., Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA. 90:1993;11825-11829.
45. Okey A.B. Enzyme induction in the cytochrome P-450 system. Pharmacol. Ther. 45:1990;241-298.
46. Guengerich, F.P., Human cytochrome P450 enzymes, in: P.R. Ortiz de Montellano (Ed.), Cytochrome P450: Structure, Mechanism and Biochemistry, New York, Plenum Press, 1995, pp. 473-536.
47. Midha, K.K., Hawes, E.M., Hubbard, J.W., Korchinski, E.D., McKay, G., The search for correlation between neuroleptic plasma levels and clinical outcome: a critical review, in: H.Y. Meltzer (Ed.), Psychopharmacology: The Third General of Progress, New York, Raven Press, 1987, pp. 1341-1351.
48. Shader R.I., Greenblatt D.J. Use of benzodiazepines in anxiety disorders. New Engl. J. Med. 328:1993;1398-1405.
49. Teboul E., Chouinard G. A guide to benzodiazepine selection. Part II: Clinical aspects. Can. J. Psychiatry. 35:1991;571-572.
50. Baumann P. Clinical pharmacokinetics of citalopram and other selective serotonin reuptake inhibitors (SSRI). Int. Clin. Psychopharmacol. 6:1992;13-20.
51. Hrdina P.D. Pharmacology of serotonin uptake inhibitors: focus on fluvoxamine. J. Psychiat. Neurosci. 16:1991;10-18.
52. Hyttel J. Citalopram-pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 6:1982;278-291.
53. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol. 9:1994;19-26.
54. Pinder R.M., Wieringa J.H. Third-generation antidepressants. Med. Res. Rev. 13:1993;259-325.
55. Potter, W.Z., Calil, H.M., Metabolites of tricyclic antidepressants: biological activity and clinical implications, in: E. Usdin (Ed.), Clinical Pharmacology in Psychiatry, New York, Elsevier, 1981, pp. 311-324.
56. Potter W.Z., Manji H.K. Antidepressants, metabolites and apparent drug resistence. Clin. Neuropharmacol. 13(Suppl. 1):1990;45-53.
57. Goff, D.C., Baldessarini, R.J., Antipsychotics, in: D.A. Ciraulo, R.I. Shader, D.J. Greenblatt, W. Creelman (Eds.), Drug Interactions in Psychiatry, 2nd ed. Baltimore, Williams & Wilkins, 1995, pp. 129-174.
58. Gram L.F., Fredricson Overø K. Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br. Med. J. 1:1972;463-465.
59. Kragh-Sørensen P., Borgå O., Garle M., Bolvig Hansen L., Hansen C.E., Hvidberg E.F., Larsen N.-E., Sjöqvist F. Effect of simultaneous treatment with low doses of perphenazine on plasma and urine concentrations of nortriptyline and 10-hydroxynortriptyline. Eur. J. Clin. Pharmacol. 11:1977;479-483.
60. Nelson J.C., Jatlow P.I. Neuroleptic effect on desipramine steady-state plasma concentrations. Am. J. Psychiatry. 137:1980;1232-1234.
61. Benfield P., Ward A. Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 32:1986;313-334.
62. Crewe H.K., Lennard M.S., Tucker G.T., Woods F.R., Haddock R.E. The effect of selective serotonin re-uptake inhibitors on cytochrome-P4502D6 (CYP2D6) activity in human liver microsomes. Br. J. Clin. Pharmacol. 34:1992;262-265.
63. Altamura A.C., Moro A.R., Perecudani M. Clinical pharmacokinetics of fluoxetine. Clin. Pharmacokinet. 26:1994;201-214.
64. Benfield P., Heel R.C., Lewis S.P. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs. 32:1986;481-508.
65. Sindrup S.H., Brøsen K., Gram L.F. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin. Pharmacol. Ther. 51:1992;288-295.
66. Sindrup S.H., Brøsen K., Gram L.F., Hallas J., Skjelbo E., Allen A., Allen G.D., Cooper S.M., Mellows G., Tasker T.C.G., Zussman B.D. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin. Pharmacol. Ther. 51:1992;278-287.
67. Van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin. Pharmacokinet. 29:1995;1-9.
68. Brøsen K., Hansen J.G., Nielsen K.K., Sindrup S.H., Gram L.F. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur. J. Clin. Pharmacol. 44:1993;349-355.
69. Bolden-Watson C., Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 52:1993;1023-1029.
70. Sindrup S.H., Brøsen K., Hansen M.G.J., Aaes-Jorgensen T., Overo K.F., Gram L.F. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther. Drug Monit. 15:1993;11-17.
71. Baumann P., Larsen F. The pharmacokinetics of citalopram. Rev. Contemp. Pharmacother. 6:1995;287-295.
72. Skjelbo E., Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br. J. Clin. Pharmacol. 34:1992;256-261.
73. Nelson J.C., Mazure C.M., Bowers M.B., Jatlow P.I. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch. Gen. Psychiatry. 48:1991;303-307.
74. Weilburg J.B., Rosenbaum J.F., Biederman J., Sachs G.S., Pollack M.H., Kelly K. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J. Clin. Psychiatry. 50:1989;447-449.
75. Fabre L.F. Trazodone dosing regimen: experience with single daily administration. J. Clin. Psychiatry. 51:1990;23-26.
76. Aranow R.B., Hudson J.I., Pope H.G., Grady T.A., Laage T.A., Bell I.R., Cole J.O. Elevated antidepressant plasma levels after addition of fluoxetine. Am. J. Psychiatry. 146:1989;911-913.
77. Bergstrom R.F., Peyton A.L., Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin. Pharmacol. Ther. 51:1992;239-248.
78. Bertschy G., Vandel S., Bandel B., Allers G., Volmat R. Fluvoxamine-tricyclic antidepressant interaction. Eur. J. Clin. Pharmacol. 40:1991;119-120.
79. Vandel S., Bertschy G., Bonin B., Nezelof S., François T.H., Vandel B., Sechter D., Bixouard P. Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology. 25:1992;202-207.
80. Vaughan D.A. Interaction of fluoxetine with tricyclic antidepressants. Am. J. Psychiatry. 145:1988;1478.
81. Wilens T.E., Biederman J., Baldessarini R.J., McDermott S.P., Puopolo P.R., Flood J.G. Fluoxetine inhibits desipramine metabolism. Arch. Gen. Psychiatry. 49:1992;752.
82. Rotzinger, S., Fang, J., Coutts, R.T., Baker, G.B., Trazodone is metabolized to m-chlorophenylpiperazine by human CYP 3A4 expressed in human cell line, in: Proc. 19th Ann. Meet. Can. Coll. Neuropsychopharmacol., Toronto, Canada, 1996, p. 37.
83. Albers L.J., Reist C., Helmeste D., Vu R., Tang S.W. Paroxetine shifts imipramine metabolism. Psychiat. Res. 59:1996;189-196.
84. Härtter S., Wetzel H., Hammes E., Hiemke C. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology. 110:1993;302-308.
85. Maskall D.D., Lam R.W. Increased plasma concentration of imipramine following augmentation with fluvoxamine. Am. J. Psychiatry. 150:1933;1566.
86. Seifritz E., Holsboertrachsler E., Hemmeter U., Eap C.B., Baumann P. Increased trimipramine plasma levels during fluvoxamine comedication. Eur. Neuropsychopharmacol. 4:1994;15-20.
87. Spina E., Pollicino A.M., Avenoso A., Campo G.M., Perucca F., Caputi A.P. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. Int. J. Clin. Pharmacol. Res. 13:1993;167-171.
88. Spina E., Pollicino A.M., Avenoso A., Campo G.M., Perucca E., Caputi A.P. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther. Drug Monit. 15:1993;243-246.
89. Wilde M.I., Plosker G.L., Benfield P. Fluvoxamine: an updated review of its pharmacology, and therapeutic use in depressive illness. Drugs. 46:1993;895-924.
90. Burke M.J., Harvey A.T., Preskorn S.H. Pharmacokinetics to the newer antidepressants. Am. J. Med. 100:1996;119-120.
91. Zussman B.D., Davie C.C., Fowles S.E., Kumar R., Lang U., Wargenau M., Sourgens H. Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. Br. J. Clin. Pharmacol. 39:1995;550-551.
92. Baettig D., Bondolfi G., Montaldi S., Amey M., Baumann P. Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study. Eur. J. Clin. Pharmacol. 44:1993;403-405.
93. Gram L.F., Hansen M.G.J., Sindrup S.H., Brøsen K., Poulsen J.H., Aaes-Jørgensen T. Citalopram: interaction studies with levomepromazine, imipramine and lithium. Ther. Drug. Monit. 15:1993;18-24.
94. Daniel D.G., Randolph C., Jaskiw G., Handel S., Williams T., Abi-Dargham A., Shoaf S., Egan M., Elkashef A., Liboff S., Linnoila M. Coadministration of fluvoxamine increases serum concentrations of haloperiodol. J. Clin. Psychopharmacol. 14:1994;340-343.
95. Goff D.C., Midha K.K., Brotman A.W., Waites M., Baldessarini R.J. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am. J. Psychiatry. 148:1991;790-794.
96. Goff D.C., Brotman A.W., Waites M., McCormick S. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am. J. Psychiatry. 147:1990;492-494.
97. Centorrino F., Baldessarini R.J., Kando J., Frankenburg F.R., Volpicelli S.A., Puopolo P.R., Flood J.G. Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine or valproate. Am. J. Psychiat. 151:1994;123-125.
98. Hiemke C., Weigmann H., Hartter S., Dahmen N., Wetzel H., Muller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J. Clin. Psychopharmacol. 14:1994;279-281.
99. Jerling M., Lindstrom L., Bondesson U., Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine; evidence from a therapeutic drug monitoring service. Ther. Drug Monit. 16:1994;368-374.
100. Koponen H.J., Leinonen E., Lepola U. Fluvoxamine increases the clozapine serum levels significantly. Eur. Neuropsychopharmacol. 6:1996;69-71.
101. Bertillson L., Carrillo J.A., Dahl M.L., Llerena A., Alm C., Bondesson U., Lindstrom L., Rodriguez de la Rubia I., Ramos S., Benitez J. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol. 38:1994;471-473.
102. Byerly M.J., DeVane L. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J. Clin. Psychopharmacol. 16:1996;177-187.
103. Dahl M.-L., Llerena A., Bondesson U., Lindström L., Bertilsson L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br. J. Clin. Pharmacol. 37:1994;71-74.
104. Pirmohamed M., Williams D., Madden S., Templeton E., Park B.K. Metabolism and bioactivation of clozapine of human liver in vitro. J. Pharmacol. Exp. Ther. 272:1995;984-990.
105. Heykants J., Huang M.-L., Mannens G., Meuldermans W., Snoeck E., Van Beijsterveldt L., Van Peer A., Woestenborghs R. The pharmacokinetics of risperidone in humans: a summary. J. Clin. Psychiatry. 55(Suppl.):1994;13-17.
106. 2 receptors. Int. Clin. Psychopharmacol. 10:1995;19-30.
107. Megens A.A., Awouters F.H., Schotte A., Meert T.F., Dugovic C., Niemegeers C.J., Leysen J.E. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology. 114:1994;9-23.
108. Van Beijsterveldt L.E., Geerts R.J., Leysen J.E., Megens A.A., Van den Eynde H.M., Meuldermans W.E., Heykants J.J. Regional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the rat. Psychopharmacology. 14:1994;53-62.
109. Grimsley S.R., Jann M.W., Carter J.G., D'Mello A.P., D'Souza M.J. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin. Pharmacol. Ther. 40:1991;10-15.
110. Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. J. Neurol. Neurosurg. Psychiatry. 55:1992;412-413.
111. Nightingale S.L. Fluoxetine labelling revised to identify phenytoin interaction and to recommend against use in nursing mothers (letter). J. Am. Med. Assoc. 271:1994;1067.
112. Pearson H.J. Interaction of fluoxetine with carbamazepine. J. Clin. Psychiatry. 51:1990;126.
113. Woods D.J., Coulter D.M., Illans P. Interaction of phenytoin and fluoxetine (letter). NZ Med. J. 107:1994;19.
114. Walley T., Pirmohamed M., Proudlove C., Maxwell D. Interaction of metoprolol and fluoxetine. Lancet. 341:1993;967-968.
115. Woolfrey S., Gammack N.S., Dewar M.S., Brown P.J.E. Fluoxetine-warfarin interaction. Br. Med. J. 307:1993;241.
116. Lasher T.A., Fleishaker J.C., Steenwyk R.C., Antal E.J. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology. 104:1991;323-327.
117. Lemberger L., Rowe H., Bosomworth J.C., Tenbarge J.B., Bergestrom R.F. The effect of fluoxetine in the pharmacokinetics and psychomotor responses of diazepam. Clin. Pharmacol. Ther. 43:1988;412-419.
118. Suchowersky O., de Vries J.D. Interaction of fluoxetine and selegiline. Can. J. Psychiatry. 35:1990;571-572.
119. Swims M.P. Potential terfenadine-fluoxetine interaction (letter). Ann. Pharmacother. 27:1993;1404-1405.
120. von Moltke K.K., Greenblatt D.J., Duan S.X., Harmatz J.S., Wright C.E., Shader R.I. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J. Clin. Psychopharmacol. 16:1996;104-112.
121. Van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 24:1993;203-220.
122. Diot P., Jonville A.P., Gerard F., Bonnelle M., Autret E. Possible interaction entre théophylline et fluvoxamine. Therapie. 46:1991;169-171.
123. Sperber A.D. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year old boy. Drug Safety. 6:1991;460-462.
124. Thomson A.H., McGovern E.M., Bennie P., Caldwell G., Smith M. Interaction between fluvoxamine and theophylline. Can. Pharm. J. 249:1992;137.
125. Bonnet P., Vandel S., Nezelof S., Sechter D., Bizouard P. Carbamazepine, Fluvoxamine. Is there a pharmacokinetic interaction? Therapie. 47:1992;165.
126. Fritze J., Unsorg B., Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiat. Scand. 84:1991;583-584.
127. Martinelli V., Bocchetta A., Palmas A.M., del Zompo M. An interaction between carbamazepine and fluvoxamine. Br. J. Clin. Pharmacol. 36:1993;613-616.
128. Perucca E., Gatti G., Cipolla G., Spina E., Barel S., Soback S., Gips M., Bialer M. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin. Pharmacol. Ther. 56:1994;471-476.
129. Fleishaker J.C., Hulst L.K. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur. J. Clin. Pharmacol. 46:1994;35-39.
130. Rasmussen B.B., Mäepää J., Pelkonen O., Loft S., Poulsen H.E., Lykkesfeldt J., Brøsen K. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br. J. Clin. Pharmacol. 39:1995;151-159.
131. Rapeport W.G., Williams S.A., Muirhead D.C., Dewland P.M., Tanner T., Wesnes K. Absence of a sertraline-mediated effect on digoxin pharmacokinetics and pharmacodynamics of carbamazepine. J. Clin. Psychiatry. 57:1996;20-23.
132. von Moltke L.L., Greenblatt D.J., Court M.H., Duan S.X., Harmatz J.S., Shader R.I. Inhibition of alprazolam and desipramine hydroxylation in vivo by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J. Clin. Psychopharmacol. 14:1995;125-131.
133. von Moltke L.L., Greenblatt D.J., Harmatz J.S., Xiang Duan S., Harrel L.M., Cotreau-Bibbo M.M., Pritchard G.A., Wright E.C., Shader R.I. Triazolam biotransformation of human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J. Pharmacol. Exp. Ther. 276:1996;370-379.
134. von Moltke L.L., Greenblatt D.J., Cotreau-Bibbo M., Duan S.X., Harmatz J.S., Shader R.I. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J. Pharmacol. Exp. Ther. 268:1994;1278-1283.
135. Gonzalez F.J., Idle J.R. Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin. Pharmacokinet. 26:1994;59-70.
136. Eyles D.W., McGrath J.J., Pond S.M. Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacology. 125:1996;214-219.
137. Fang J., Gorrod J.W., Kajbaf M., Lamb J.H., Nalyor S. Investigation of the neuroleptic drug haloperidol and its metabolites using tandem mass spectrometry. Int. J. Mass Spectrom. Ion Process. 122:1993;121-131.
138. Van der Schyf C.J., Castagnoli K., Usuki E., Fouda H.G., Rimoldi J.M., Castagnoli N. Jr. Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice. Chem. Res. Toxicol. 7:1994;281-285.
139. +-like neurotoxicity of a pyridinium metabolite derived from haloperidol: In vivo microdialysis and in vitro mitochondrial studies. J. Pharmacol. Exp. Ther. 268:1994;380-387.
140. Subramanyam B., Rollema H., Woolf T., Castagnoli N. Jr. Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem. Biophys. Res. Commun. 166:1990;238-244.
141. Baker G.B., Coutts R.T., Holt A. Metabolism and chirality in psychopharmacology. Biol. Psychiatry. 36:1994;211-213.
142. Coutts R.T., Baker G.B. Metabolic implications of chiral centres in psychotropic drugs. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 13:1989;405-417.
143. Coutts R.T., Baker G.B. Implications of chirality and geometric isomerism in some psychoactive drugs and their metabolites. Chirality. 1:1989;99-120.
144. Drayer D.E. Problems in therapeutic drug monitoring: the dilemma of enantiomeric drugs in man. Ther. Drug. Monit. 10:1988;1-7.
145. Jamali F., Mehvar R., Pasutto F.M. Enantioselective aspects of drug action and disposition: therapeutic pitfalls. J. Pharm. Sci. 78:1989;695-715.
146. Caldwell J. Importance of stereospecific bioanalytical monitoring in drug development. J. Chromatogr. A. 719:1996;3-13.
147. Eichelbaum M. Pharmacokinetic and pharmacodynamic consequences of stereoselective drug metabolism in man. Biochem. Pharmacol. 37:1988;93-96.
148. Kaye B. Chiral drug metabolism: a perspective. Biochem. Soc. Trans. 19:1991;456-459.
149. Nation R.L. Chirality in new drug development: clinical pharmacokinetic considerations. Clin. Pharmacokinet. 27:1994;249-254.
150. Spahn-Langguth H., Hahn G., Mutschler E., Möhrke W., Langguth P. Enantiospecific high-performance liquid chromatographic assay with fluorescence detection for the monamine oxidase inhibitor tranylcypromine and its applicability in pharmacokinetic studies. J. Chromatogr. Biomed. Appl. 485:1992;229-237.
151. Testa B. Chiral aspects of drug metabolism. Trends Pharmacol. Sci. 7:1986;60-64.
152. Wong D.T., Bymaster F.P., Reid L.R., Mayles D.A., Krushinski J.H., Robertson D.W. Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology. 8:1993;337-344.
153. Hyttel J., Bøgesø K.P., Perregaard J., Sánchez C. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J. Neural Transm. 88:1992;157-160.
154. Stevens J.C., Wrighton S.A. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J. Pharmacol. Exp. Ther. 266:1993;964-971.